wjlk,
A ton of research on NDGA since Friday and a lot of reputable cancer research ongoing plus other indications. Study of this drug is old (30 years+) and toxicity has been a problem but the potential efficacy must be of value for the research to continue trying to find the correct synthetic formulation or compound. If this is snake oil, NIH plus others are dumping a lot of money on studies for various indications. Sure it could all be a waste but who knows.
The license to NAPO is $1.5 million needed dollars so what do we have to lose. The way it was released, unexcusable.
COC is non-event and means nothing except updating for change in management team.
"the obviously scripted latest CC being cutoff before any probing questions could be taken" Two analyst asked questions and there were no more questions was the way I heard it. Lack of interest, absolutely.
Am I happy with management? No, no, no, no, no!!!!! Am I reassesing my investment? Yes. As it stands now, giving it into or through Q2 to make up my mind. ALS is keeping me here.
Rod
News 
Market Data 
Discover 
AI
